LLY - Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals | Benzinga
Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating Eli Lilly and Co (NYSE:LLY) in comparison to its major competitors within the Pharmaceuticals industry. By analyzing critical financial metrics, market position, and growth potential, our objective is to provide valuable insights for investors and offer a deeper understanding of company's performance in the industry.
Eli Lilly and Co Background
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| Eli Lilly and Co | |||||||
| 128.61 | |||||||
| 65.84 | |||||||
| 19.75 | |||||||
| 19.91% | |||||||
| $3.03 | |||||||
| $7.57 | |||||||
| 28.1% | |||||||
| Novo Nordisk A/S | |||||||
| 46.31 | |||||||
| 36.11 | |||||||
| 16.69 | |||||||
| 22.01% | |||||||
| $28.51 | |||||||
| $55.85 | |||||||
| 36.95% | |||||||
| Merck & Co Inc | |||||||
| 894.50 | |||||||
| 8.44 | |||||||
| 5.31 | |||||||
| -3.11% | |||||||
| $-0.77 | |||||||
| $10.72 | |||||||
| 5.78% | |||||||
| AstraZeneca PLC | |||||||
| 35.88 | |||||||
| 5.41 | |||||||
| 4.66 | |||||||
| 2.52% | |||||||
| $2.18 | |||||||
| $9.72 | |||||||
| 7.29% | |||||||
| Novartis AG | |||||||
| 22.58 | |||||||
| 4.05 | |||||||
| 4.15 | |||||||
| 19.99% | |||||||
| $4.18 | |||||||
| $8.75 | |||||||
| 7.39% | |||||||
| Pfizer Inc | |||||||
| 68.62 | |||||||
| 1.62 | |||||||
| 2.45 | |||||||
| -3.62% | |||||||
| $-1.77 | |||||||
| $6.69 | |||||||
| -41.34% | |||||||
| Sanofi SA | |||||||
| 19.89 | |||||||
| 1.44 | |||||||
| 2.31 | |||||||
| -0.75% | |||||||
| $0.42 | |||||||
| $8.15 | |||||||
| 6.5% | |||||||
| Bristol-Myers Squibb Co | |||||||
| 12.51 | |||||||
| 3.33 | |||||||
| 2.23 | |||||||
| 6.03% | |||||||
| $4.45 | |||||||
| $8.73 | |||||||
| 0.62% | |||||||
| GSK PLC | |||||||
| 13.17 | |||||||
| 4.84 | |||||||
| 2.14 | |||||||
| 2.64% | |||||||
| $1.16 | |||||||
| $5.63 | |||||||
| 9.16% | |||||||
| Zoetis Inc | |||||||
| 30.20 | |||||||
| 14 | |||||||
| 8.28 | |||||||
| 10.42% | |||||||
| $0.83 | |||||||
| $1.49 | |||||||
| 8.48% | |||||||
| Takeda Pharmaceutical Co Ltd | |||||||
| 36.21 | |||||||
| 0.95 | |||||||
| 1.54 | |||||||
| 1.53% | |||||||
| $314.89 | |||||||
| $731.71 | |||||||
| 1.33% | |||||||
| Viatris Inc | |||||||
| 222.20 | |||||||
| 0.64 | |||||||
| 0.87 | |||||||
| -3.7% | |||||||
| $-0.07 | |||||||
| $1.6 | |||||||
| -1.0% | |||||||
| Dr Reddy's Laboratories Ltd | |||||||
| 18.94 | |||||||
| 3.69 | |||||||
| 3.64 | |||||||
| 5.29% | |||||||
| $22.42 | |||||||
| $42.2 | |||||||
| 6.57% | |||||||
| Jazz Pharmaceuticals PLC | |||||||
| 17.91 | |||||||
| 1.82 | |||||||
| 2.05 | |||||||
| 2.61% | |||||||
| $0.29 | |||||||
| $0.9 | |||||||
| 4.1% | |||||||
| Corcept Therapeutics Inc | |||||||
| 24.13 | |||||||
| 4.65 | |||||||
| 5.25 | |||||||
| 6.43% | |||||||
| $0.03 | |||||||
| $0.13 | |||||||
| 31.39% | |||||||
| Average | |||||||
| 104.5 | |||||||
| 6.5 | |||||||
| 4.4 | |||||||
| 4.88% | |||||||
| $26.91 | |||||||
| $63.73 | |||||||
| 5.94% |